Sell in May? I bought these 3 magnificent growth stocks last month!

Edward Sheldon believes these three growth stocks could generate fantastic returns for his investment portfolio in the years ahead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s an old stock market adage that states investors should ‘sell in May and go away’. However, I don’t pay much attention to this. In fact, last month, I actually bought three growth stocks for my portfolio.

Interested to know what companies I invested in? Read on and I’ll tell you.

Well positioned for growth

First up, we have FTSE 100 industrial company Ashtead (LSE: AHT). It’s one of the world’s largest construction equipment rental companies.

I’ve owned this stock for about 18 months now. My view is that it’s an excellent play on US infrastructure spending.

The reason I bought more? Well I noticed that guidance from FTSE 250 company Keller – which specialises in getting ground ready to build on and has a lot of exposure to the US – was strong. This reinforced my view that companies with exposure to the US construction industry like Ashtead are well positioned for growth.

A risk here is that the company could announce that it’s going to spend money on new equipment. This could hit profits, and the share price, in the near term.

Taking a five-year view though, I’m excited about the growth potential here.

‘Transformative profit potential’

The second stock I bought was software company Sage (LSE: SGE). It experienced a sharp share price fall on the back of slightly lower-than-expected guidance and I bought the dip.

Now, in hindsight, I pulled the trigger a little early. Since my purchase, the stock’s continued to fall (a lot of software stocks have been weak in the last few weeks).

However, taking a five-to-10-year view, I’m confident I’ll be rewarded. I see this company as a great play on the ‘digital transformation’ theme. As small- and medium-sized businesses move to adopt cloud-based accounting and payroll solutions, Sage should benefit. It’s worth pointing out here that UK portfolio manager Nick Train believes Sage has ‘transformative profit potential’ in the long run.

Economic weakness is a risk to consider here. This could impact smaller businesses and hurt Sage’s growth.

With the software stock now trading on a forward-looking P/E ratio in the mid-20s though (versus 31 for US rival Intuit), I think it looks attractive.

Sky-high demand for its products

Last but not least we have Danish pharmaceutical company Novo Nordisk (NYSE: NVO) – the maker of weight-loss drugs Wegovy and Ozempic. I started a small position here earlier in the year and last month I increased my holding.

The reason I bought this stock is quite simple – the global obesity epidemic. Across the world, there are more than a billion people with obesity today. And this is creating high demand for weight-loss drugs such as Wegovy and Ozempic.

In Novo Nordisk’s recent quarterly results, it reported net sales growth of 24% year on year. It also raised its full-year guidance.

Given the success Novo Nordisk’s having, other pharma companies are scrambling to develop new weight-loss drugs. These could be a threat to Novo’s future sales.

With the annual market for weight-loss drugs forecast to hit $130bn by 2030 though, I see room for multiple players.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Ashtead Group Plc, Novo Nordisk, and Sage Group Plc. The Motley Fool UK has recommended Novo Nordisk and Sage Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Growth Shares

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Up 56%? See the stunning Tesla share price forecast for 2025

The Tesla share price has taken an absolute battering, but that may tempt bargain-seeking investors willing to embrace extreme volatility.

Read more »

Google office headquarters
Growth Shares

The 2025 stock market sell-off: why now’s the time to consider buying ‘Magnificent 7’ growth stocks

Many of the ‘Magnificent 7’ are currently down 15% or more from their highs. And Edward Sheldon believes it’s time…

Read more »

Investing Articles

Are BAE Systems shares still a bargain near a 52-week high?

Charlie Carman evaluates where BAE Systems shares could go next as geopolitical turmoil drives global military expenditure to record levels.

Read more »

Girl buying groceries in the supermarket with her father.
Investing Articles

What on earth’s going on with the Unilever share price?

Andrew Mackie examines the reasons behind the lack of direction in the Unilever share price over the past few years.

Read more »

Investing Articles

Up another 35% in 2025 – can the Rolls-Royce share price keep climbing forever?

Can nothing stop the Rolls-Royce share price? It's been shooting to the stars for three years now but has to…

Read more »

Investing Articles

Could buying Nvidia stock now be like buying Amazon for pennies in 2000?

History isn't a predictor as to what happens next in the stock market, but our writer thinks it can still…

Read more »

Light bulb with growing tree.
Investing Articles

Down 73%, can the ITM Power share price ever recover?

Christopher Ruane sees a lot to like about ITM Power, but reckons the share price is where it is for…

Read more »

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Down 20% since February despite excellent 2024 results, is IAG’s share price set to soar again?

IAG’s share price tumbled recently on factors that look speculative to me, so a bargain might be in view. To…

Read more »